TLX News: First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy - 22nd Nov 2022, 7:59am

[annb0t]

MELBOURNE, Australia, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that a first patient has been dosed in a Phase II investigator-initiated study of TLX101 in combination with external beam radiation therapy (EBRT) in patients with recurrent high-grade gliomas (HGG), including glioblastoma multiforme (GBM). (PRNewsfoto/Telix Pharmaceuticals Limited)

TLX101 (4-L-[131I] iodo-phenylalanine, or 131I-IPA) is one of Telix's lead ther...

>>> Read more: First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy